The disclosure announces that Avio Smart Market Stack Limited (ASMS) initiated strategic discussions with Mediciti Institute of Medical Sciences (MIMS), Hyderabad, as part of its strategy to build a scalable Diagnostics & Healthcare business. The discussions aimed to explore opportunities for research collaboration, clinical validation, and adoption of advanced molecular diagnostic technologies.
During the engagement, Huwel Lifesciences, ASMS' strategic molecular diagnostics partner, showcased its portfolio of indigenous diagnostic technologies and ongoing innovations in molecular diagnostics. The technologies presented included solutions for tuberculosis, multidrug-resistant tuberculosis (MDR-TB), sepsis, HPV screening, hepatitis, antimicrobial resistance (AMR) detection, respiratory diseases, and environmental surveillance.
Huwel Lifesciences highlighted its fully integrated diagnostics platform spanning assay development, reagent manufacturing, instrumentation, software, and data management, designed to deliver scalable and affordable diagnostic solutions for healthcare providers.
The discussions focused on collaborative research, clinical validation studies, real-world evidence generation, and opportunities for adoption and deployment of Huwel's diagnostic technologies within Mediciti's healthcare ecosystem. The organizations explored the possibility of pilot programs and product evaluations across selected departments to assess their impact on routine diagnostic workflows.
Mediciti Institute of Medical Sciences was identified as a strategic partner due to its strong clinical expertise, academic leadership, patient volumes, and research infrastructure.
Management Commentary:
- Mr. Vidyasagar Reddy, Managing Director, Avio Smart Market Stack, stated that ASMS has made a significant commitment to building a scalable Diagnostics & Healthcare business through its strategic partnership with Huwel Lifesciences. The objective is focused on accelerating real-world adoption of these technologies by leading healthcare institutions.
- Dr. Shesheer Kumar, Founder and Director, Huwel Lifesciences, emphasized that Mediciti's strong research capabilities and clinical expertise make it an ideal partner for advancing scientific validation and evaluating the impact of innovative diagnostics in real-world healthcare settings.
The engagement underscores the growing importance of collaborations between healthcare innovators and academic medical institutions in accelerating the development, validation, adoption and commercialization of next-generation diagnostic technologies.
As part of its Diagnostics & Healthcare growth strategy, ASMS is actively building market access channels for advanced diagnostic technologies through partnerships with healthcare institutions, government programs, research organizations, and industry stakeholders. Through its partnership with Huwel Lifesciences, the company is working to accelerate validation, adoption, procurement, and large-scale deployment of indigenous diagnostic solutions across India and international markets.
Financial Impact: Not quantified in the disclosure.